MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
Globe Newswire•27/07/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.